ADC Therapeutics is a biotechnology company that focuses on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and haematological cancers. The company employs monoclonal antibodies specific to particular tumour antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine-based warheads to selectively kill cancer cells.